SAB Biotherapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SABS research report →
Range $11 – $13
Price Chart
About the company
SAB Biotherapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
- CEO
- Samuel J. Reich
- IPO
- 2021
- Employees
- 86
- HQ
- Miami Beach, FL, US
Get TickerSpark's AI analysis on SABS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $253.15M
- P/E
- -3.13
- Fwd P/E
- 26.76
- PEG
- 0.02
- P/S
- 0.00
- P/B
- 1.29
- EV/EBITDA
- -3.13
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -40.04%
- ROIC
- -38.41%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-3,081,586+11.2%
- Op Income
- $-48,953,363
- Net Income
- $13.27M+138.9%
- EPS
- $0.22+106.0%
- OCF Growth
- -30.6%
- FCF Growth
- -32.0%
- 52W High
- $5.15
- 52W Low
- $2.44
- 50D MA
- $3.07
- 200D MA
- $3.60
- Beta
- 0.58
- RSI (14)
- 43
- Avg Volume
- 633.60K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
SAB BIO said SAFEGUARD enrollment remains on track for completion in Q4, while the company highlighted FDA Fast Track for SAB-142 and a cash runway into 2028.· November 5, 2026
- SAFEGUARD adult and adolescent cohorts are fully enrolled and screening is closed; management reaffirmed completion of enrollment in Q4.
- FDA granted Fast Track designation to SAB-142 in October, adding more frequent FDA interactions, rolling BLA review eligibility, and possible Priority Review.
- The company plans to dose first patients in the investigator-led PRISE study this quarter, with 7 sites planned across the U.S., Europe and the UK.
- Cash and investments were $205 million at September 30, 2026, including $13.4 million from warrant exercises, and management said this funds operations through 2028.
- R&D and G&A increased year over year as SAB BIO advanced the clinical program and added headcount.
- Management emphasized SAB-142’s potential differentiation versus Tzield via fewer dosing days, low immunogenicity, and possible redosing over a longer treatment period.
SAB BIO reported $205 million in cash, cash equivalents and investment securities at September 30, 2026, including $13.4 million in gross proceeds from warrant exercises. R&D expense was $18.1 million versus $9 million a year ago, and G&A expense was $7.8 million versus $3.7 million. Other income was $3.6 million versus $58.1 million last year, which contributed to net loss of $22.3 million compared with net income of $45.4 million in the prior-year quarter. Management reiterated that the existing cash balance should fund operations through 2028. Looking ahead, the company reaffirmed SAFEGUARD enrollment completion in Q4 and topline data in the second half of 2027; PRISE is expected to dose first patients this quarter.
Samuel Reich said the company is focused on advancing SAB-142 as a disease-modifying therapy for type 1 diabetes and framed the third quarter as strong execution on clinical priorities. He highlighted robust SAFEGUARD enrollment momentum, the upcoming PRISE study as an expansion opportunity, and the FDA Fast Track designation as meaningful procedural progress. His tone was optimistic but measured, repeatedly tying the program’s value to preserving beta cells and enabling broader patient access over time.
Lucy To said SAB BIO ended the quarter with $205 million in cash, cash equivalents and investment securities and expects that balance to fund operations through 2028. She cited $13.4 million of gross proceeds from warrant exercises, R&D of $18.1 million versus $9 million last year due mainly to trial costs and headcount, and G&A of $7.8 million versus $3.7 million due mainly to personnel and stock compensation. She also noted other income fell to $3.6 million from $58.1 million because 2025 included changes in warrant liability fair value, and said the company remains positioned to support SAFEGUARD and PRISE while preparing for commercial readiness.
Analysts pressed management on what will matter most in next year’s data versus Tzield, and management said the primary endpoint is C-peptide preservation, with HbA1c, CGM, safety and low immunogenicity also important for differentiation. Questions also focused on PRISE design, timing and patient cohorts; management said PRISE mirrors SAFEGUARD except for time from diagnosis, with cohorts out to 2 years and baseline C-peptide plus age used for stratification. On safety, management said the DMC saw no new signal and approved the pediatric step-down, and on burn rate they said PRISE was already included in the budget. Management also said redosing has occurred according to plan but did not disclose the number of redosed patients.
The company is moving toward several near-term catalysts: completing SAFEGUARD enrollment in Q4, starting PRISE dosing this quarter, and potentially releasing topline data in the second half of 2027. Management also believes Fast Track and SAB-142’s fully human design could help with regulatory efficiency, redosing, and long-term differentiation. They characterized physician interest as high and said the Tzield launch is helping validate demand for earlier treatment.
The call still leaves the core efficacy question unanswered until next year’s data, especially around C-peptide and glycemic control versus Tzield. Management did not disclose how many patients have been redosed, and the PRISE study is investigator-led so timing is not yet guided. The quarter also showed higher operating expenses and a swing from prior-year net income to a $22.3 million net loss, largely because last year benefited from warrant-related fair value gains.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 89.6%
- Shares Outstanding
- 90.09M
- Float Shares
- 80.72M
of shares held by institutions
92 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Caligan Partners LP | 7.97M | 0 |
| Vivo Capital, LLC | 6.92M | ▼ 384.90K |
| Perceptive Advisors LLC | 6.63M | ▲ 195.76K |
| Adage Capital Partners Gp, L.L.C. | 6.41M | ▲ 3.00M |
| Ra Capital Management, L.P. | 4.40M | 0 |
| Balyasny Asset Management L.P. | 3.76M | 0 |
| Blackrock, Inc. | 3.57M | ▲ 506.06K |
| Vanguard Capital Management LLC | 3.09M | ▲ 115.61K |
| Commodore Capital LP | 2.87M | ▼ 1.53M |
| Millennium Management LLC | 2.75M | ▼ 283.61K |
| Spruce Street Capital LP | 2.20M | 0 |
| Sanofi | 2.20M | ▲ 2.20M |
Held by 77 ETFs
Biggest fund positions in SABS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 17, 26 | Kropotova Alexandra | other | 473 |
| Jun 25, 26 | Kropotova Alexandra | other | 988 |
| Mar 24, 26 | Kropotova Alexandra | other | 988 |
| Feb 3, 26 | Sullivan Eddie Joe | other | 3,000,000 |
| Feb 3, 26 | Reich Samuel J | other | 4,800,000 |
| Feb 3, 26 | Bausch Christoph Lawrence | other | 1,800,000 |
| Feb 3, 26 | Kropotova Alexandra | other | 2,400,000 |
| Feb 3, 26 | To Lucy | other | 2,400,000 |
| Jan 5, 26 | Jain Rita | other | 240,000 |
| Jan 5, 26 | ZACCARDELLI DAVID | other | 240,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SABS coverage
Recent articles, reports, and earnings notes.
No research on SABS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SABS report →SAB Biotherapeutics, Inc. (SABS) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
What SAB Biotherapeutics (SABS) Said on Its Q3 Earnings Call
marketbeat.com · Nov 6
SAB Biotherapeutics, Inc. (SABS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights
globenewswire.com · Nov 5
SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET
globenewswire.com · Oct 29
SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform
marketbeat.com · Oct 23
SAB BIO to Participate in Chardan 10th Annual Healthcare Conference
globenewswire.com · Oct 14
SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
globenewswire.com · Oct 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.